Pages that link to "Q40991569"

The following pages link to Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. (Q40991569):

Displaying 29 items.

• Principles of interleukin (IL)-6-type cytokine signalling and its regulation (Q24530173) (← links)
• Inflammation and Alzheimer's disease (Q28138617) (← links)
• Interleukin 6 and liver regeneration (Q33969763) (← links)
• Lack of knowledge: breast cancer and the soluble interleukin-6 receptor (Q34096100) (← links)
• Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells (Q34102346) (← links)
• Use of biologics in the treatment of childhood rheumatic diseases (Q34109021) (← links)
• Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis (Q34218604) (← links)
• The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis (Q35429154) (← links)
• Regulation of TRPM7 Function by IL-6 through the JAK2-STAT3 Signaling Pathway (Q35968944) (← links)
• Interleukin-6 trans-signaling in the senescent mouse brain is involved in infection-related deficits in contextual fear conditioning. (Q36975857) (← links)
• Pregnancy-associated genes contribute to antiluteolytic mechanisms in ovine corpus luteum (Q37346020) (← links)
• Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance? (Q37453953) (← links)
• IL-6/IL-6R as a potential key signaling pathway in prostate cancer development (Q37968599) (← links)
• IL-6 as a keystone cytokine in health and disease (Q38433045) (← links)
• Interleukin-6 "Trans-Signaling" and Ischemic Vascular Disease: The Important Role of Soluble gp130. (Q38934729) (← links)
• Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery (Q38958166) (← links)
• Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures (Q39059671) (← links)
• Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor (Q39459586) (← links)
• Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling (Q39938165) (← links)
• Role of soluble gp130 in the tumour necrosis factor-alpha expression and its production by peripheral blood mononuclear cells (Q42027456) (← links)
• Signal transducer gp130: biochemical characterization of the three membrane-proximal extracellular domains and evaluation of their oligomerization potential (Q42157929) (← links)
• Effect of soluble interleukin-6 receptor alpha and interleukin-6 secreted by polymorphonuclear leukocytes on tumor necrosis factor-alpha expression and its production by peripheral blood mononuclear cells. (Q42982710) (← links)
• Cellular and Oxidative Mechanisms Associated with Interleukin-6 Signaling in the Vasculature (Q46252086) (← links)
• Interleukin-6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors. (Q55077160) (← links)
• Therapeutic Targeting of the Proinflammatory IL-6-JAK/STAT Signalling Pathways Responsible for Vascular Restenosis in Type 2 Diabetes Mellitus (Q61807469) (← links)
• Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling (Q64052490) (← links)
• The influence of age and gender on serum dehydroepiandrosterone sulphate (DHEA-S), IL-6, IL-6 soluble receptor (IL-6 sR) and transforming growth factor beta 1 (TGF-beta1) levels in normal healthy blood donors (Q78197123) (← links)
• Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain (Q81060793) (← links)
• A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity (Q90266648) (← links)